ReviewCureus2026

Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease.

Mukosolu F Obi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.